Whereas GLP-1R agonists (exenatide, liraglutide, semaglutide) improve glucose disposal in response to increased insulin secretion, reduce food intake and body weight, and ameliorate insulin resistance and hepatic steatosis[16], their efficacy in late stages of metabolic liver injury remains questionable[17]. Here, INS is linked to fatty liver disease.